Cancer treatment systems maker BSD Medical Corp (BSDM) has landed a distribution deal with Appleton Medical Services Inc. for its MicroThermX Microwave Ablation system for soft tissue ablation (destruction).
Appletonis a leading distributor of minimally-invasive surgical products with a rich history of selling specialty surgical devices made by some of the major medical companies in the U.S. It has a dedicated sales force specialized in marketing a select range of surgical products for the interventional radiology market, the target market for BSD Medical’s ablation products.
The agreement provides Appleton the rights to distribute the MicroThermX products in Missouri, Louisiana, Oklahoma, Mississippi, Arkansas, Kansas, Iowa, Nebraska and Texas.
The deal represents a part of BSD Medical’s ongoing efforts to establish a dedicated specialty distribution network for the MicroThermX products in the U.S. The company has strategized to use the network of specialty distribution firms, which market products in the interventional radiology area. Moreover, BSD Medical is expanding its marketing and sales force to support the roll-out of its MicroThermX products.
BSD Medical introduced the innovative MicroThermX system in the U.S. in December 2010. Subsequently, the Utah-based company successfully launched its first MicroThermX system in Europe in January 2011.
The MicroThermX system leverages BSD Medical’s proprietary synchronous phased array technology to deliver precision-guided microwave energy to ablate soft tissues using a single-patient-use disposable antenna.
The minimally-invasive MicroThermX system has been developed to provide treatments as a stand-alone therapy and has applications in open surgical and percutaneous (via needle-puncture of the skin) ablation procedures. As such, it can be used by both surgeons and interventional radiologists.
The MTX-180 system offers several key advantages over the legacy radio frequency-based systems including delivery of wider ablation zones in less time employing microwave energy.
BSD Medical competes with established players like Boston Scientific (BSX) and Angiodynamics (ANGO) in the thermal ablation market. The global market potential for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.
ANGIODYNAMICS (ANGO): Free Stock Analysis Report
Be the first to comment